NCT05570955View on ClinicalTrials.gov

Deucravacitinib Adherence Study

NAActive, not recruitingINTERVENTIONAL

Enrollment

40

Participants

Timeline

Start Date

July 24, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

February 28, 2026

Conditions

Psoriasis

Interventions

BEHAVIORAL

Text reminder

weekly text to remind use of drug

Trial Locations (1)

27157

Wake Forest University Health Sciences Department of Dermatology, Winston-Salem

Sponsors

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Wake Forest University Health Sciences

OTHER

NCT05570955 - Deucravacitinib Adherence Study | Biotech Hunter | Biotech Hunter